Proclara Biosciences to Participate in Mizuho Biotechnology Conference 2017: CNS “Deep Management” Day

CAMBRIDGE, Mass., Sept. 12, 2017 -- Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that company management will participate in the Mizuho Biotechnology Conference 2017: CNS “Deep Management” Day on Tuesday, September 19, 2017 in Boston, MA.

 

About Proclara Biosciences

Proclara Biosciences is a biotechnology company advancing product candidates developed based on its proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the GAIM technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and orphan systemic amyloidoses. Proclara has developed a pipeline of drug candidates that use GAIM to target the common amyloid protein conformation, dissociating and preventing the formation of misfolded protein assemblies, and blocking the cell-to-cell transmission of toxic aggregates. The company’s lead program NPT088 is currently being evaluated in a Phase 1b trial for Alzheimer’s disease.

For more information, please visit proclarabio.com.


Media Contact
Sarah Sutton
Ten Bridge Communications
(518) 932-3680
sarah@tenbridgecommunications.com

Investor Contact 
Hannah Deresiewicz
Stern Investor Relations, Inc.
(212) 362-1200
hannahd@sternir.com